Safety and Efficacy of Oliceridine Fumarate Combined with Remimazolam in Elderly Patients Undergoing Painless Gastroscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600125370

Enrollment

Unknown

Registered

2026-05-26

Start date

2026-05-26

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Experimental Group:Oliceridine fumarate combined with remimazolam

Control group:Sufentanil combined with propofol

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 65 years; 2. ASA Class I - III; 3. BMI 18 - 28 kg/m^2; 4. Scheduled elective painless gastroscopy; 5. Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of long-term use of opioids or sedative-hypnotics; 2. Severe or decompensated cardiopulmonary disease; 3. Patients with a difficult airway; 4. Patients allergic to the study drug; 5. Severe hepatic or renal insufficiency.

Design outcomes

Primary

Measure	Time frame
Incidence of hypoxemia;incidence of hypotension;	—

Secondary

Measure	Time frame
Intraoperative recording of recovery and quality (sedation success rate, induction time, recovery time, time to discharge);	—

Countries

China

Contacts

Public ContactDong Li

Quzhou People’s Hospital

1192547210@qq.com+86 570 312 1425

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026